|
| Status |
Public on Sep 07, 2023 |
| Title |
Targeting TCA cycle through Cuproptosis confers Synthetic Lethality to ARID1A Deficiency Hepatocellular Carcinoma |
| Organisms |
Homo; Homo sapiens |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
Other
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Mar 24, 2023 |
| Last update date |
Sep 08, 2023 |
| Contact name |
TAO XING |
| Organization name |
Peking University Cancer Hospital
|
| Street address |
Beiing
|
| City |
Beiing |
| State/province |
Beiing |
| ZIP/Postal code |
100000 |
| Country |
China |
| |
|
| Platforms (2) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
| GPL30128 |
Illumina NovaSeq 6000 (Homo) |
|
| Samples (30)
|
|
| This SuperSeries is composed of the following SubSeries: |
| GSE228175 |
Targeting TCA cycle through Cuproptosis confers Synthetic Lethality to ARID1A Deficiency Hepatocellular Carcinoma [Cut&Run] |
| GSE228176 |
Targeting TCA cycle through Cuproptosis confers Synthetic Lethality to ARID1A Deficiency Hepatocellular Carcinoma [ATAC-Seq] |
| GSE228177 |
Genome-wide CRISPR-Cas9 screen reveals selective vulnerability of ARID1A deficiency Hepatocellular Carcinoma |
|
| Relations |
| BioProject |
PRJNA948437 |
Less...
More...